BC Extra | Jan 31, 2020
Financial News

Jan. 30 Financial Quick Takes: Vertex, Black Diamond, Alexion, Alector, DBV

Trikafta sales bolster Vertex’s revenue  Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) handily beat consensus estimates with its 4Q19 earnings Thursday, bolstered by the $420 million in sales newly approved CF therapy Trikafta elexacaftor/tezacaftor/ivacaftor brought in during its...
BioCentury | Nov 8, 2019
Emerging Company Profile

Arkuda emerges from Atlas with genetic dementia program

Atlas-founded Arkuda is developing compounds for frontotemporal dementia due to genetic lysosomal deficits that could be applied to other neurodegenerative diseases linked to lysosomal dysfunction. Arkuda Therapeutics Inc. debuted Thursday with a $44 million series...
BC Extra | Jul 20, 2019
Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

Polyphor ends PRISM trials  The Swiss immuno-oncology company Polyphor AG (SIX:POLN) closed the Phase III PRISM MDR and PRISM UDR trials of its IV formulation of murepavadin for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) after...
BC Extra | Jul 9, 2019
Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
BC Innovations | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
BC Innovations | Apr 11, 2019
Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
BC Innovations | Mar 21, 2019
Emerging Company Profile

A Passage to optimal CNS vectors

Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched...
BC Week In Review | Sep 9, 2013
Company News

Galantos, Neurodyn deal

Neurodyn acquired lead Alzheimer's candidate Memogain from Galantos for an undisclosed sum. Neurodyn said Memogain completed preclinical testing and plans to start Phase I testing late this year. Memogain is a prodrug of galantamine, an...
BC Week In Review | Mar 12, 2012
Company News

A&G, Mayo Clinic deal

A&G granted the clinic worldwide, non-exclusive rights to patents and antibody reagents for the detection and measurement of progranulin ( PGRN ; PCDGF ) in blood. Mayo said it plans to offer a test by late 2012...
BC Innovations | May 12, 2011
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Progranulin (PGRN; PCDGF); histone deacetylases (HDACs) Cell culture studies suggest that small molecule agonists of PGRN expression could help treat...
Items per page:
1 - 10 of 18